Promis Neurosciences Stock Investor Sentiment
| PMN Stock | USD 1.03 0.07 7.29% |
About 71 percent of all ProMIS Neurosciences' investors are curious in acquiring. The analysis of the overall investor sentiment regarding ProMIS Neurosciences suggests that quite a few traders are confidant. ProMIS Neurosciences' investing sentiment overview a quick insight into current market opportunities from investing in ProMIS Neurosciences. Many technical investors use ProMIS Neurosciences stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ProMIS |
ProMIS Neurosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ProMIS Neurosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about ProMIS Neurosciences that are available to investors today. That information is available publicly through ProMIS media outlets and privately through word of mouth or via ProMIS internal channels. However, regardless of the origin, that massive amount of ProMIS data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ProMIS Neurosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ProMIS Neurosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ProMIS Neurosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ProMIS Neurosciences alpha.
ProMIS Neurosciences Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/05/2024 |
2 | Acquisition by Gordon Michael S of 76931 shares of ProMIS Neurosciences at 1.2228 subject to Rule 16b-3 | 09/16/2024 |
3 | Bell and MacLean advance the next generation of mining operations in Canada, driving enhanced safety and sustainability | 09/17/2024 |
4 | Acquisition by Shafmaster Madge K. of 60000 shares of ProMIS Neurosciences at 1.2511 subject to Rule 16b-3 | 09/20/2024 |
5 | Acquisition by Shafmaster Madge K. of 70000 shares of ProMIS Neurosciences at 1.2808 subject to Rule 16b-3 | 09/23/2024 |
6 | Acquisition by Shafmaster Madge K. of 70000 shares of ProMIS Neurosciences at 1.3004 subject to Rule 16b-3 | 09/24/2024 |
7 | Disposition of 50000 shares by Eugene Williams of ProMIS Neurosciences at 8.4 subject to Rule 16b-3 | 09/25/2024 |
8 | Acquisition by Kirwin Patrick D. of 40000 shares of ProMIS Neurosciences at 1.11 subject to Rule 16b-3 | 10/03/2024 |
9 | Acquisition by Warma Neil K of 1144122 shares of ProMIS Neurosciences at 1.15 subject to Rule 16b-3 | 10/08/2024 |
10 | ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of 0. ... | 11/14/2024 |
11 | Acquisition by Altstiel Larry Douglas of 175000 shares of ProMIS Neurosciences at 1.0 subject to Rule 16b-3 | 11/18/2024 |
12 | ProMIS Neurosciences stock hits 52-week low at 0.91 - Investing.com | 11/20/2024 |
Check out ProMIS Neurosciences Hype Analysis, ProMIS Neurosciences Correlation and ProMIS Neurosciences Performance. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.